SCHEMBL13153012

SCHEMBL13153012

COc1ccc(CC(C)(C)C)cc1N

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.67
▸ ALDH1A1 P00352 6/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ MEN1 O00255 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ THRB P10828 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ CYP19A1 P11511 3/20 0.47
▸ LMNA P02545 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ CA2 P00918 1/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ APP P05067 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ PARP1 P09874 1/20 0.41
▸ ADRA2B P18089 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ TUBB4A P04350 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10725608 0.86 GAA (0.62) GAAALDH1A1CYP3A4MEN1MAPT
SCHEMBL13153014 0.85 ALDH1A1 (0.67) GAAALDH1A1CYP3A4MAPTCYP19A1
SCHEMBL24038015 0.84 GAA (0.46) GAAALDH1A1CYP3A4MEN1MAPT
SCHEMBL74008 0.82 CA2 (0.63) ALDH1A1CYP3A4CYP19A1CA2KDM4E
SCHEMBL24038031 0.81 GAA (0.65) GAAALDH1A1CYP3A4MEN1MAPT
SCHEMBL6865547 0.80 GAA (1.00) GAAALDH1A1CYP3A4MEN1MAPT
SCHEMBL31090146 0.80 GAA (0.77) GAAALDH1A1CYP3A4MEN1MAPT
SCHEMBL13181092 0.79 GAA (0.69) GAAALDH1A1CYP3A4MEN1MAPT
SCHEMBL9917308 0.79 CRHBP (0.47) GAAALDH1A1MEN1MAPTKMT2A
SCHEMBL357294 0.79 GAA (0.74) GAAALDH1A1CYP3A4MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170014419-A1 MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) 2017-01-19 — — US disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 — — US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 GAA 272/4885ALDH1A1 617/4885CYP3A4 1945/4885
US-20170014419-A1 MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS AGTR2, MME, AGTR1 GAA 2009/4885ALDH1A1 2036/4885CYP3A4 3652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback